BiomarkerPlus
Multimodal AI-derived spatial biomarkers, developed with pharmaceutical partners to inform drug discovery and patient stratification.
Find alternatives to BiomarkerPlus
What it does
- Drug discovery
Features 3
- Stratification biomarkersBiomarkers that predict the best treatment per patient by analyzing subgroups of good and bad responders.
- Screening biomarkersBiomarkers that identify patients with a particular disease characteristic to define and accelerate trial enrolment.
- Risk score biomarkersBiomarkers that predict disease course such as outcome, overall survival and metastatic relapse.
Sources
- Pricing
-
Official documentation · 6 Sep 2026
No price appears on the page and Owkin publishes no rate card.
- Description
-
Official documentation · 6 Sep 2026
Summarised from the page's own title, <h1> and meta description, fetched 2026-09-06.
- Sold within
-
Official documentation · 6 Sep 2026
Presented as its own offering with its own page, engaged directly rather than bundled into another Owkin product. Corrected at apply time: parent set to null.
standalonemeans no parent OFFERING stands between the buyer and the product; the vendor's own company name is not such an offering. - URL
-
Official documentation · 6 Sep 2026
Fetched 2026-09-06: HTTP 200, <title> 'Spatial Biomarkers for AI Drug Discovery | Owkin', <h1> 'Multimodal AI-powered spatial biomarkers'.
- Intended for
-
"These models have been designed to be interpretable by researchers and medical experts leading to a multiscale understanding of the disease"; case-study testimonial from Prof. Nicolas Girard, Head of Thorax Institute Curie Montsouris
Also from Owkin
-
K Pro AI agent
Research agent that answers biomedical questions across Owkin's clinical and molecular datasets and ranks therapeutic targets and gene candidates.
Something wrong here? Send a correction — quote this product id: owkin-biomarkerplus.